Related Experiment Video
Updated: Jan 22, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and
Daniël A Lionarons1, David C Hancock1, Sareena Rana2
1Oncogene Biology, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Abstract:
RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and reveal that RAC1P29S activates PAK, AKT, and a gene expression program initiated by the SRF/MRTF transcriptional pathway, which results in a melanocytic to mesenchymal phenotypic switch. Mice with ubiquitous expression of RAC1P29S from the endogenous locus develop lymphoma. When expressed only in melanocytes, RAC1P29S cooperates with oncogenic BRAF or with NF1-loss to promote tumorigenesis. RAC1P29S also drives resistance to BRAF inhibitors, which is reversed by SRF/MRTF inhibitors. These findings establish RAC1P29S as a promoter of melanoma initiation and mediator of therapy resistance, while identifying SRF/MRTF as a potential therapeutic target.
Insights
The RAC1 P29S mutation promotes melanoma development and therapy resistance by activating specific pathways. Inhibiting the SRF/MRTF pathway can reverse resistance, offering a potential therapeutic strategy for melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- RAC1 P29 is a frequent mutation in cutaneous melanoma.
- Understanding RAC1's role is crucial for melanoma treatment.
Purpose of the Study:
- Investigate the function of RAC1 P29S in melanoma.
- Identify therapeutic targets for RAC1-driven melanoma.
Main Methods:
- Studied RAC1 P29S in mouse models.
- Analyzed gene expression and protein activation.
- Assessed drug resistance mechanisms.
Main Results:
- RAC1 P29S activates PAK, AKT, and SRF/MRTF pathways.
- This leads to a melanocytic to mesenchymal transition.
- RAC1 P29S drives melanoma initiation and BRAF inhibitor resistance.
- Resistance is reversed by SRF/MRTF inhibitors.
Conclusions:
- RAC1 P29S is a key driver of melanoma initiation.
- It mediates resistance to BRAF inhibitors.
- SRF/MRTF pathway is a potential therapeutic target in melanoma.
More Related Videos
Related Concept Videos
Development of Antibiotic Resistance
Transcription Factors
The Eukaryotic Promoter Region
Factors Affecting Drug Response: Overview
Switching of BJT
Cut-off Mode ("Off" State): In this state, both the emitter-base and collector-base junctions are...
Gene Therapy

